Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SERENTIL is an injectable small-molecule antipsychotic approved in 1970 for psychiatric indications. The product operates as a dopamine antagonist typical of first-generation antipsychotics. It represents a legacy therapeutic class with established clinical utility in managing psychotic disorders.
Mature product with modest competitive pressure (30%) and minimal active career pipeline linked to this brand, indicating a consolidation-focused team rather than growth-phase expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SERENTIL offers limited career growth opportunity given zero linked job postings and approaching LOE status. Roles on this brand focus on defending market share, managing payer relationships, and optimizing positioning in a mature, competitive market rather than building new capabilities.
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.